RecruitingPhase 2NCT07428616

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Sponsor

Exelixis

Enrollment

100 participants

Start Date

May 21, 2026

Study Type

INTERVENTIONAL

Conditions

Meningioma

Summary

The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Zanzalintinib for people with meningioma. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGZanzalintinib

Administered as specified in the treatment arm.

Locations(12)

University of Alabama

Birmingham, Alabama, United States

Mayo Clinic_Arizona

Phoenix, Arizona, United States

Mayo Clinic_Jacksonville

Jacksonville, Florida, United States

Baptist Health Miami Cancer Institute

Miami, Florida, United States

Washington University School of Medicine

Bay Saint Louis, Mississippi, United States

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

Mayo Clinic_Rochester

Rochester, New York, United States

Duke University

Durham, North Carolina, United States

UT MD Anderson Cancer Center

Houston, Texas, United States

UT Health San Antonio Mays Cancer Center

San Antonio, Texas, United States

Inova Center for Personalized Health

Fairfax, Virginia, United States

UW Carbone Cancer Center

Madison, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07428616

Related Trials

Embolization for Meningioma

NCT054165671 location

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

NCT052782084 locations

Search for Circulating Tumour Cells in the Blood and/or Cerebrospinal Fluid in Patients With Recurrent Aggressive Meningiomas: Proof-of-concept Study

NCT073981701 location

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

NCT074934471 location

Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial

NCT061265882 locations